MET and neoplasm: For instance, IDR models were used to characterize the relationship between the concentrations of c-mesenchymal–epithelial transition factor (cMet) inhibitor PF02341066, a targeted therapy candidate small molecule, and the inhibition of cMet phosphorylation (biomarker), as well as TGI (pharmacological response) in human tumor xenograft (GTL16 gastric carcinoma) mouse models and then further assess the relationship between biomarker and TGI efficacy [75].